686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2

• Tao Huang,
• An Song,
• Ryan Stafford,
• Maria Jose Costa,
• Zhiqiang Ku,
• Jing-Tyan Ma,
• Krista McCutcheon,
• Xiaoye Liu,
• Heyu Chen,
• Kyu Hong,
• Ningyan Zhang,
• Zhiqiang An,
• Cheng Cheng Zhang,
• X Charlene Liao

Affiliations

Tao Huang

1Immune-Onc Therapeutics, Palo Alto, CA, USA

An Song

1Immune-Onc Therapeutics, Palo Alto, CA, USA

Ryan Stafford

1Immune-Onc Therapeutics, Palo Alto, CA, USA

Maria Jose Costa

1Immune-Onc Therapeutics, Palo Alto, CA, USA

Zhiqiang Ku

2University of Texas Health Science Center, Houston, TX, USA

Jing-Tyan Ma

1Immune-Onc Therapeutics, Palo Alto, CA, USA

Krista McCutcheon

1Immune-Onc Therapeutics, Palo Alto, CA, USA

Xiaoye Liu

3University of Texas Southwestern, Dallas, TX, USA

Heyu Chen

3University of Texas Southwestern, Dallas, TX, USA

Kyu Hong

1Immune-Onc Therapeutics, Palo Alto, CA, USA

Ningyan Zhang

2University of Texas Health Science Center, Houston, TX, USA

Zhiqiang An

2University of Texas Health Science Center, Houston, TX, USA

Cheng Cheng Zhang

3University of Texas Southwestern, Dallas, TX, USA

X Charlene Liao

1Immune-Onc Therapeutics, Palo Alto, CA, USA